



## Emefcy Group Ltd (ASX: EMC) Update - Timing of Issue of Deferred Consideration Shares

Melbourne, Australia and Caesarea, Israel, 23 June, 2016

As previously advised to ASX in its announcement on 12 April 2016, the Company is required to issue a total of 22,500,000 ordinary shares (**Deferred Consideration Shares**) to the vendors of Emefcy Limited, as part of the consideration for the equity interests in Emefcy Limited under the share exchange and purchase agreement dated as of October 1, 2015 between the Company and those vendors.

18,514,193 of the Deferred Consideration Shares have been issued to the Emefcy vendors. 3,985,807 of the Deferred Consideration Shares (**Remaining Deferred Consideration Shares**) have not yet been issued to two Emefcy vendors, however, due to delays in compliance with certain Israeli tax requirements.

The Company initially obtained a waiver of ASX Listing Rule 14.7 to allow the Company to delay issuing some of the Deferred Consideration Shares until 12 June 2016. The Company has obtained a further waiver to allow the Company to delay issuing the Remaining Deferred Consideration Shares until the relevant Israeli tax requirements have been complied with (but no later than 3 August 2016).

For further information, please contact:

Ross Kennedy, Company Secretary and Advisor to the Board  
E: rossk@emefcygroup.com T: +61 (0)409 524 442

### About Emefcy Group Limited (EMC)

The Company offers a commercially-proven wastewater treatment solution potentially disrupting large existing markets and addressing the growing global need for clean water. Its initial technology, SABRE – The Spiral Aerobic Biofilm Reactor is a modular decentralised wastewater treatment solution using 90% less energy than conventional technology. Future generation SABRE2 and SUBRE are higher capacity solutions being developed for broader markets. The Company's future technology under development, EBR - The Electrogenic Bioreactor is being designed to harvest electricity from highly-loaded industrial wastewater that is typically very costly to treat. The energy's value has the potential to completely offset other treatment operating costs.

Any forward-looking statements in this announcement are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management.